Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiation Tolerance | 22 | 2021 | 480 | 4.360 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 33 | 2024 | 5246 | 2.870 |
Why?
|
Lung Neoplasms | 49 | 2024 | 13245 | 2.470 |
Why?
|
Radiation-Sensitizing Agents | 9 | 2021 | 345 | 2.360 |
Why?
|
Relative Biological Effectiveness | 7 | 2019 | 312 | 1.980 |
Why?
|
Radiosurgery | 14 | 2024 | 1342 | 1.960 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 8 | 2015 | 146 | 1.800 |
Why?
|
DNA Repair | 19 | 2021 | 2038 | 1.630 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 7 | 2021 | 1725 | 1.320 |
Why?
|
Radiobiology | 5 | 2020 | 89 | 1.220 |
Why?
|
Radiation Injuries | 9 | 2020 | 1182 | 1.190 |
Why?
|
DNA Damage | 13 | 2021 | 2439 | 1.170 |
Why?
|
DNA Breaks, Double-Stranded | 11 | 2019 | 607 | 1.130 |
Why?
|
Rad51 Recombinase | 12 | 2016 | 188 | 1.070 |
Why?
|
Recombination, Genetic | 12 | 2013 | 1526 | 1.050 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 8 | 2020 | 1659 | 0.980 |
Why?
|
Neoplasms | 24 | 2024 | 22032 | 0.960 |
Why?
|
Tumor Suppressor Protein p53 | 10 | 2019 | 2912 | 0.960 |
Why?
|
Radiation Oncology | 4 | 2024 | 563 | 0.940 |
Why?
|
Radiotherapy | 11 | 2024 | 1504 | 0.940 |
Why?
|
Fanconi Anemia | 4 | 2016 | 324 | 0.830 |
Why?
|
Thoracic Wall | 3 | 2020 | 199 | 0.810 |
Why?
|
Molecular Targeted Therapy | 7 | 2021 | 2796 | 0.770 |
Why?
|
Radiotherapy Dosage | 13 | 2021 | 2896 | 0.720 |
Why?
|
Antineoplastic Agents | 16 | 2021 | 13591 | 0.700 |
Why?
|
Phthalazines | 3 | 2018 | 382 | 0.700 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2016 | 801 | 0.690 |
Why?
|
BRCA1 Protein | 6 | 2015 | 1147 | 0.670 |
Why?
|
Head and Neck Neoplasms | 8 | 2024 | 2882 | 0.600 |
Why?
|
Esophagus | 4 | 2021 | 1023 | 0.590 |
Why?
|
Fibroblasts | 6 | 2010 | 4087 | 0.590 |
Why?
|
Uncertainty | 2 | 2013 | 751 | 0.580 |
Why?
|
DNA Replication | 4 | 2021 | 1410 | 0.570 |
Why?
|
Protein Kinase Inhibitors | 7 | 2020 | 5629 | 0.560 |
Why?
|
Cell Line, Tumor | 22 | 2024 | 16886 | 0.550 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2019 | 714 | 0.540 |
Why?
|
Recombinases | 1 | 2016 | 66 | 0.520 |
Why?
|
Osteopontin | 1 | 2017 | 301 | 0.490 |
Why?
|
Gastroenterology | 1 | 2021 | 571 | 0.490 |
Why?
|
Protons | 2 | 2021 | 1112 | 0.480 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2020 | 5249 | 0.480 |
Why?
|
Fanconi Anemia Complementation Group A Protein | 2 | 2011 | 50 | 0.470 |
Why?
|
Esophagitis | 1 | 2015 | 163 | 0.450 |
Why?
|
Reactive Oxygen Species | 2 | 2019 | 2129 | 0.440 |
Why?
|
Cell Survival | 9 | 2021 | 5781 | 0.430 |
Why?
|
Small Molecule Libraries | 1 | 2019 | 724 | 0.430 |
Why?
|
Endonucleases | 1 | 2016 | 369 | 0.430 |
Why?
|
Cisplatin | 5 | 2023 | 1645 | 0.420 |
Why?
|
Radiation Pneumonitis | 3 | 2016 | 102 | 0.420 |
Why?
|
Thoracic Neoplasms | 1 | 2015 | 266 | 0.420 |
Why?
|
Mutation | 24 | 2024 | 29915 | 0.410 |
Why?
|
Piperazines | 3 | 2018 | 2511 | 0.400 |
Why?
|
ras Proteins | 2 | 2014 | 1049 | 0.400 |
Why?
|
Humans | 107 | 2024 | 758406 | 0.360 |
Why?
|
DNA | 5 | 2021 | 7199 | 0.360 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2015 | 1791 | 0.360 |
Why?
|
Apoptosis | 6 | 2019 | 9468 | 0.350 |
Why?
|
Etoposide | 1 | 2011 | 630 | 0.340 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2023 | 2276 | 0.340 |
Why?
|
Fanconi Anemia Complementation Group Proteins | 1 | 2010 | 97 | 0.340 |
Why?
|
Quinazolines | 3 | 2014 | 1360 | 0.330 |
Why?
|
Neoplasm Staging | 8 | 2024 | 11152 | 0.330 |
Why?
|
Combined Modality Therapy | 13 | 2021 | 8530 | 0.320 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2015 | 4023 | 0.320 |
Why?
|
Photons | 4 | 2019 | 581 | 0.310 |
Why?
|
Organoplatinum Compounds | 1 | 2010 | 405 | 0.310 |
Why?
|
Pneumonectomy | 1 | 2015 | 1111 | 0.300 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2015 | 3527 | 0.290 |
Why?
|
Guidelines as Topic | 1 | 2013 | 1386 | 0.280 |
Why?
|
DNA-Binding Proteins | 10 | 2016 | 9574 | 0.270 |
Why?
|
Cell Cycle Proteins | 5 | 2011 | 3442 | 0.270 |
Why?
|
G1 Phase | 2 | 2015 | 403 | 0.270 |
Why?
|
Chromosome Breakage | 1 | 2006 | 159 | 0.270 |
Why?
|
Signal Transduction | 7 | 2018 | 23342 | 0.260 |
Why?
|
Congresses as Topic | 2 | 2024 | 799 | 0.260 |
Why?
|
Cobalt Radioisotopes | 2 | 2016 | 75 | 0.260 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2016 | 419 | 0.250 |
Why?
|
Organs at Risk | 4 | 2019 | 358 | 0.240 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4485 | 0.240 |
Why?
|
Medical Oncology | 3 | 2023 | 2312 | 0.240 |
Why?
|
Cell Proliferation | 6 | 2021 | 10416 | 0.230 |
Why?
|
Chromones | 1 | 2024 | 148 | 0.230 |
Why?
|
Endodeoxyribonucleases | 2 | 2016 | 164 | 0.220 |
Why?
|
Mice, Nude | 3 | 2019 | 3602 | 0.220 |
Why?
|
Pharmaceutical Preparations | 2 | 2021 | 1090 | 0.210 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3709 | 0.210 |
Why?
|
Radiation Dosage | 5 | 2017 | 1956 | 0.210 |
Why?
|
Chromatin | 1 | 2014 | 2938 | 0.200 |
Why?
|
Animals | 29 | 2021 | 167768 | 0.200 |
Why?
|
Radiation, Ionizing | 4 | 2011 | 251 | 0.200 |
Why?
|
Mice | 18 | 2021 | 81101 | 0.190 |
Why?
|
Mitomycin | 2 | 2013 | 262 | 0.190 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3671 | 0.190 |
Why?
|
Cell Line | 9 | 2015 | 15591 | 0.190 |
Why?
|
Parental Leave | 1 | 2021 | 91 | 0.180 |
Why?
|
Female | 45 | 2024 | 390323 | 0.180 |
Why?
|
Neoplastic Stem Cells | 3 | 2017 | 1346 | 0.180 |
Why?
|
Transplantation, Heterologous | 2 | 2019 | 2378 | 0.180 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9160 | 0.180 |
Why?
|
Melanoma, Experimental | 1 | 2003 | 559 | 0.180 |
Why?
|
Physicians, Women | 2 | 2024 | 495 | 0.180 |
Why?
|
Breast | 1 | 2009 | 1963 | 0.180 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 11709 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2020 | 9273 | 0.170 |
Why?
|
Cranial Irradiation | 2 | 2020 | 390 | 0.170 |
Why?
|
Alginates | 1 | 2021 | 248 | 0.170 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2022 | 167 | 0.170 |
Why?
|
Aged, 80 and over | 18 | 2021 | 58683 | 0.170 |
Why?
|
Clinical Trials as Topic | 7 | 2021 | 7985 | 0.160 |
Why?
|
S Phase | 1 | 2000 | 422 | 0.160 |
Why?
|
Aged | 26 | 2024 | 168218 | 0.160 |
Why?
|
Histones | 2 | 2011 | 2577 | 0.160 |
Why?
|
Aniline Compounds | 1 | 2024 | 1068 | 0.150 |
Why?
|
Bicarbonates | 1 | 2019 | 292 | 0.150 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2019 | 242 | 0.150 |
Why?
|
Genes, p53 | 1 | 2000 | 712 | 0.150 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2020 | 262 | 0.150 |
Why?
|
Policy | 1 | 2021 | 511 | 0.150 |
Why?
|
Oxygen | 1 | 2009 | 4191 | 0.150 |
Why?
|
Male | 34 | 2024 | 358747 | 0.140 |
Why?
|
Lung | 6 | 2019 | 9985 | 0.140 |
Why?
|
Middle Aged | 26 | 2024 | 219568 | 0.140 |
Why?
|
Oxidative Stress | 1 | 2008 | 3099 | 0.140 |
Why?
|
Gene Conversion | 3 | 2008 | 67 | 0.140 |
Why?
|
Societies, Medical | 3 | 2024 | 3891 | 0.140 |
Why?
|
Carcinoma, Medullary | 1 | 1997 | 115 | 0.140 |
Why?
|
Thiazoles | 1 | 2024 | 1510 | 0.130 |
Why?
|
Tumor Burden | 4 | 2017 | 1893 | 0.130 |
Why?
|
Cesium Radioisotopes | 1 | 2016 | 38 | 0.130 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2019 | 270 | 0.130 |
Why?
|
Research Report | 1 | 2019 | 367 | 0.130 |
Why?
|
Phenylurea Compounds | 1 | 2019 | 529 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 8 | 2020 | 6493 | 0.120 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2019 | 646 | 0.120 |
Why?
|
Brain Neoplasms | 4 | 2020 | 8981 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2004 | 2825 | 0.120 |
Why?
|
Cell Cycle | 3 | 2018 | 2930 | 0.120 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2024 | 2858 | 0.120 |
Why?
|
History, 20th Century | 5 | 2006 | 2772 | 0.120 |
Why?
|
Neoplasm Metastasis | 4 | 2020 | 4901 | 0.120 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2018 | 471 | 0.120 |
Why?
|
Linear Energy Transfer | 1 | 2015 | 152 | 0.110 |
Why?
|
Rhabdomyosarcoma | 1 | 1997 | 358 | 0.110 |
Why?
|
Protein Kinase C-alpha | 1 | 2014 | 113 | 0.110 |
Why?
|
Cell Division | 2 | 2000 | 4458 | 0.110 |
Why?
|
Tumor Stem Cell Assay | 1 | 2013 | 115 | 0.110 |
Why?
|
Flow Cytometry | 2 | 2016 | 5864 | 0.110 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 1115 | 0.110 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2019 | 3574 | 0.110 |
Why?
|
Pyrazines | 1 | 2019 | 1198 | 0.110 |
Why?
|
Biopsy | 2 | 2019 | 6768 | 0.110 |
Why?
|
Treatment Outcome | 15 | 2024 | 64378 | 0.100 |
Why?
|
Meta-Analysis as Topic | 1 | 1998 | 1373 | 0.100 |
Why?
|
Plasmids | 4 | 2004 | 2275 | 0.100 |
Why?
|
RNA Interference | 2 | 2011 | 2836 | 0.100 |
Why?
|
Carcinoma, Lobular | 1 | 1997 | 489 | 0.100 |
Why?
|
Thymus Neoplasms | 1 | 2015 | 274 | 0.100 |
Why?
|
Radiography | 2 | 2015 | 6954 | 0.100 |
Why?
|
Exodeoxyribonucleases | 1 | 2013 | 192 | 0.100 |
Why?
|
NIH 3T3 Cells | 1 | 2013 | 670 | 0.100 |
Why?
|
Cells, Cultured | 5 | 2011 | 18940 | 0.100 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2013 | 425 | 0.100 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 4429 | 0.100 |
Why?
|
Thymidine | 1 | 2011 | 299 | 0.100 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2011 | 94 | 0.090 |
Why?
|
Models, Theoretical | 2 | 2020 | 3561 | 0.090 |
Why?
|
Lymphocytes | 1 | 2019 | 2610 | 0.090 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2016 | 1335 | 0.090 |
Why?
|
Fluorescent Antibody Technique | 2 | 2015 | 2470 | 0.090 |
Why?
|
Models, Biological | 5 | 2021 | 9460 | 0.090 |
Why?
|
Antigens, Nuclear | 2 | 2008 | 184 | 0.090 |
Why?
|
Cell Hypoxia | 1 | 2013 | 655 | 0.090 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2011 | 122 | 0.090 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 275 | 0.090 |
Why?
|
Oncogenes | 1 | 2016 | 1220 | 0.090 |
Why?
|
Fanconi Anemia Complementation Group C Protein | 1 | 2010 | 21 | 0.090 |
Why?
|
Rectal Neoplasms | 1 | 2019 | 1152 | 0.090 |
Why?
|
Germany | 3 | 1998 | 868 | 0.090 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20055 | 0.090 |
Why?
|
History, 19th Century | 2 | 2006 | 720 | 0.090 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1705 | 0.090 |
Why?
|
Exonucleases | 1 | 2009 | 44 | 0.080 |
Why?
|
Genes, erbB-1 | 1 | 2010 | 160 | 0.080 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1997 | 1096 | 0.080 |
Why?
|
Breast Neoplasms | 5 | 2009 | 21017 | 0.080 |
Why?
|
Education, Medical, Graduate | 1 | 2021 | 2359 | 0.080 |
Why?
|
Retrospective Studies | 11 | 2024 | 80168 | 0.080 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2013 | 675 | 0.080 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7378 | 0.080 |
Why?
|
Immunologic Factors | 1 | 2018 | 1585 | 0.080 |
Why?
|
Frozen Sections | 1 | 2009 | 153 | 0.080 |
Why?
|
Benzimidazoles | 1 | 2014 | 855 | 0.080 |
Why?
|
Transcriptional Activation | 3 | 2011 | 1752 | 0.080 |
Why?
|
Cell Line, Transformed | 1 | 2010 | 869 | 0.080 |
Why?
|
Cross-Linking Reagents | 1 | 2011 | 685 | 0.080 |
Why?
|
3T3 Cells | 2 | 2000 | 1084 | 0.070 |
Why?
|
Reference Values | 1 | 2015 | 4919 | 0.070 |
Why?
|
Hippocampus | 1 | 2020 | 3736 | 0.070 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 2872 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1613 | 0.070 |
Why?
|
Tumor Cells, Cultured | 2 | 2013 | 6127 | 0.070 |
Why?
|
Transfection | 2 | 2013 | 5779 | 0.070 |
Why?
|
Soft Tissue Neoplasms | 1 | 1995 | 1152 | 0.070 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2011 | 730 | 0.070 |
Why?
|
Respiration | 1 | 2013 | 1654 | 0.070 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 2 | 2008 | 168 | 0.070 |
Why?
|
Neutrophils | 1 | 2019 | 3765 | 0.070 |
Why?
|
Genomics | 2 | 2023 | 5790 | 0.070 |
Why?
|
Movement | 1 | 2013 | 1474 | 0.070 |
Why?
|
France | 2 | 1998 | 499 | 0.070 |
Why?
|
Prospective Studies | 5 | 2022 | 54137 | 0.060 |
Why?
|
Sarcoma | 1 | 1997 | 1785 | 0.060 |
Why?
|
Linear Models | 1 | 2016 | 5862 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10748 | 0.060 |
Why?
|
Microscopy, Fluorescence | 1 | 2013 | 2646 | 0.060 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2006 | 1055 | 0.060 |
Why?
|
Crossing Over, Genetic | 2 | 2001 | 95 | 0.060 |
Why?
|
Mitochondria | 1 | 2018 | 3584 | 0.060 |
Why?
|
Genotype | 3 | 2017 | 12945 | 0.060 |
Why?
|
Manure | 1 | 2004 | 12 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5404 | 0.060 |
Why?
|
Base Sequence | 4 | 2015 | 12436 | 0.060 |
Why?
|
Drug Resistance | 1 | 2010 | 1593 | 0.060 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2023 | 106 | 0.060 |
Why?
|
Sphingomyelin Phosphodiesterase | 1 | 2003 | 82 | 0.060 |
Why?
|
Ubiquitin | 1 | 2008 | 837 | 0.050 |
Why?
|
Spinal Cord | 1 | 2011 | 1814 | 0.050 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2006 | 1693 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2013 | 2215 | 0.050 |
Why?
|
Ammonia | 1 | 2004 | 236 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2011 | 10146 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2014 | 3485 | 0.050 |
Why?
|
Bioreactors | 1 | 2004 | 244 | 0.050 |
Why?
|
Biomedical Research | 1 | 2018 | 3418 | 0.050 |
Why?
|
Immunotherapy | 1 | 2018 | 4641 | 0.050 |
Why?
|
Catheter Ablation | 2 | 2014 | 2740 | 0.050 |
Why?
|
Homeodomain Proteins | 1 | 2011 | 2413 | 0.050 |
Why?
|
DNA Mutational Analysis | 2 | 2010 | 4106 | 0.050 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2008 | 1312 | 0.050 |
Why?
|
Adult | 11 | 2024 | 219935 | 0.050 |
Why?
|
Tumor Microenvironment | 3 | 2019 | 3840 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2017 | 4313 | 0.050 |
Why?
|
Calcium Chloride | 1 | 2021 | 78 | 0.050 |
Why?
|
Monte Carlo Method | 2 | 2019 | 1256 | 0.050 |
Why?
|
Survival Analysis | 3 | 2020 | 10112 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2017 | 39059 | 0.050 |
Why?
|
Postoperative Care | 2 | 1997 | 1471 | 0.040 |
Why?
|
Treatment Failure | 2 | 2017 | 2640 | 0.040 |
Why?
|
History, 21st Century | 1 | 2006 | 1573 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2024 | 895 | 0.040 |
Why?
|
Genes, BRCA2 | 1 | 2002 | 603 | 0.040 |
Why?
|
Inflammation | 1 | 2019 | 10718 | 0.040 |
Why?
|
Rats | 3 | 2000 | 23679 | 0.040 |
Why?
|
Trans-Activators | 1 | 2008 | 2860 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2111 | 0.040 |
Why?
|
Mice, SCID | 1 | 2003 | 2626 | 0.040 |
Why?
|
Cystectomy | 1 | 2023 | 697 | 0.040 |
Why?
|
Cell Growth Processes | 1 | 2019 | 384 | 0.040 |
Why?
|
Neoplasms, Experimental | 1 | 2003 | 1228 | 0.040 |
Why?
|
Time Factors | 5 | 2020 | 39872 | 0.040 |
Why?
|
Ohio | 1 | 2019 | 321 | 0.040 |
Why?
|
Genomic Instability | 2 | 2015 | 704 | 0.040 |
Why?
|
Codon | 1 | 2000 | 602 | 0.040 |
Why?
|
Triazines | 1 | 2020 | 310 | 0.040 |
Why?
|
Cultural Diversity | 1 | 2021 | 365 | 0.040 |
Why?
|
Laboratories | 1 | 2021 | 460 | 0.040 |
Why?
|
Standard of Care | 1 | 2021 | 550 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2019 | 881 | 0.040 |
Why?
|
United States | 4 | 2024 | 72136 | 0.040 |
Why?
|
Cohort Studies | 4 | 2024 | 41256 | 0.040 |
Why?
|
Analysis of Variance | 2 | 2016 | 6234 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6313 | 0.040 |
Why?
|
Alanine | 1 | 2000 | 603 | 0.040 |
Why?
|
Prognosis | 4 | 2019 | 29557 | 0.040 |
Why?
|
Gene Amplification | 1 | 2001 | 1085 | 0.040 |
Why?
|
Saccharomyces cerevisiae Proteins | 2 | 2008 | 1851 | 0.030 |
Why?
|
Disease Progression | 3 | 2020 | 13468 | 0.030 |
Why?
|
Survival Rate | 3 | 2019 | 12721 | 0.030 |
Why?
|
Up-Regulation | 2 | 2008 | 4113 | 0.030 |
Why?
|
Disease Models, Animal | 3 | 2018 | 18119 | 0.030 |
Why?
|
Early Detection of Cancer | 2 | 2022 | 3211 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6821 | 0.030 |
Why?
|
DNA Primers | 2 | 2015 | 2816 | 0.030 |
Why?
|
Nuclear Proteins | 2 | 2008 | 5786 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 296 | 0.030 |
Why?
|
Switzerland | 1 | 1996 | 323 | 0.030 |
Why?
|
Radiation Injuries, Experimental | 1 | 1996 | 88 | 0.030 |
Why?
|
Embryo, Mammalian | 1 | 2001 | 1674 | 0.030 |
Why?
|
Faculty, Medical | 1 | 2024 | 1192 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 2006 | 17617 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2023 | 3617 | 0.030 |
Why?
|
Drug Combinations | 1 | 2021 | 2020 | 0.030 |
Why?
|
Comet Assay | 1 | 2015 | 72 | 0.030 |
Why?
|
Models, Genetic | 2 | 2002 | 3441 | 0.030 |
Why?
|
Quality of Life | 1 | 2016 | 13285 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2016 | 12440 | 0.030 |
Why?
|
Benzamides | 1 | 2020 | 1368 | 0.030 |
Why?
|
Imidazoles | 1 | 2020 | 1179 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2022 | 20500 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 15773 | 0.030 |
Why?
|
Fluorouracil | 1 | 1997 | 1631 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 1997 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 25956 | 0.020 |
Why?
|
Europe | 1 | 1998 | 3420 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2000 | 6209 | 0.020 |
Why?
|
Genes, Reporter | 2 | 2008 | 1527 | 0.020 |
Why?
|
Methotrexate | 1 | 1997 | 1719 | 0.020 |
Why?
|
HeLa Cells | 1 | 2016 | 3096 | 0.020 |
Why?
|
Rabbits | 1 | 1996 | 4772 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2001 | 3609 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 1997 | 2943 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2018 | 8506 | 0.020 |
Why?
|
Calcium | 1 | 2022 | 5721 | 0.020 |
Why?
|
Menopause | 1 | 1997 | 1639 | 0.020 |
Why?
|
Gene Expression | 1 | 2001 | 7583 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2000 | 8143 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 3099 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 590 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8426 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 2 | 2011 | 2800 | 0.020 |
Why?
|
Preoperative Care | 1 | 1997 | 2249 | 0.020 |
Why?
|
Research | 1 | 1996 | 1976 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4567 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5031 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2000 | 5098 | 0.020 |
Why?
|
BRCA2 Protein | 2 | 2002 | 798 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 1997 | 2690 | 0.020 |
Why?
|
Massachusetts | 1 | 2019 | 8823 | 0.020 |
Why?
|
Methylation | 1 | 2009 | 1080 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 611 | 0.020 |
Why?
|
Cricetulus | 1 | 2008 | 815 | 0.020 |
Why?
|
DNA, Single-Stranded | 1 | 2008 | 352 | 0.020 |
Why?
|
Binding Sites | 2 | 2006 | 6036 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 787 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2002 | 4876 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3593 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11070 | 0.020 |
Why?
|
CHO Cells | 1 | 2008 | 1389 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2009 | 1492 | 0.020 |
Why?
|
Replication Protein A | 1 | 2004 | 52 | 0.020 |
Why?
|
Cricetinae | 1 | 2008 | 2426 | 0.010 |
Why?
|
Research Design | 1 | 2020 | 6157 | 0.010 |
Why?
|
Fertilizers | 1 | 2004 | 24 | 0.010 |
Why?
|
Waste Disposal, Fluid | 1 | 2004 | 32 | 0.010 |
Why?
|
Phosphorylation | 2 | 2006 | 8297 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2011 | 1958 | 0.010 |
Why?
|
Incidence | 1 | 2022 | 21272 | 0.010 |
Why?
|
Radiology | 1 | 1997 | 2102 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9404 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2011 | 2907 | 0.010 |
Why?
|
Glioma | 1 | 1997 | 3418 | 0.010 |
Why?
|
Transcription Factors | 1 | 2001 | 12094 | 0.010 |
Why?
|
Kinetics | 1 | 2008 | 6371 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2006 | 1745 | 0.010 |
Why?
|
Gene Deletion | 1 | 2008 | 2666 | 0.010 |
Why?
|
Serine | 1 | 2004 | 828 | 0.010 |
Why?
|
Risk | 1 | 2011 | 9599 | 0.010 |
Why?
|
Chloramphenicol O-Acetyltransferase | 1 | 1999 | 221 | 0.010 |
Why?
|
Comorbidity | 1 | 2014 | 10495 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2010 | 2055 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2008 | 3432 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 13961 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2004 | 2497 | 0.010 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2008 | 1887 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2008 | 2895 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12604 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2011 | 12096 | 0.010 |
Why?
|
Young Adult | 2 | 2014 | 58808 | 0.010 |
Why?
|
Swine | 1 | 2004 | 5892 | 0.010 |
Why?
|
Protein Binding | 1 | 2004 | 9311 | 0.010 |
Why?
|
Air Pollutants | 1 | 2004 | 2842 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2002 | 11892 | 0.000 |
Why?
|
Risk Factors | 1 | 2011 | 73809 | 0.000 |
Why?
|